Dedicated to Conquering Heart Failure
A clinical-stage biotechnology company focused on developing innovative anti-inflammatory therapies for the treatment of cardiovascular disease
COVID-19 and CVD
Cardiol has been approved by the FDA for a Phase II/III clinical trial to test the efficacy of CardiolRx™ in improving outcomes for COVID-19 patients with cardiovascular disease (CVD).
Learn More
Acute Myocarditis
Cardiol is planning a Phase II international trial of acute myocarditis, the most common cause of sudden cardiac death in people under 35 years of age.
Learn More
Heart Failure
Committed to conquering a serious condition that affects more than 26 million people globally.
Learn More
LATEST NEWS
All News
Press Release
Cardiol Announces Upsize to Previously Announced Bought Deal Public Offering
May 06, 2021
Cardiol Announces Upsize to Previously Announced Bought Deal Public Offering
Press Release
Cardiol Therapeutics Announces $15 Million Bought Deal Public Offering
May 05, 2021
Cardiol Therapeutics Announces $15 Million Bought Deal Public Offering
Press Release
Cardiol Therapeutics Announces First Patient Enrolled in LANCER, a Phase II/III Outcomes Trial in High-risk Patients Hospitalized with COVID-19
April 28, 2021
Cardiol Therapeutics Announces First Patient Enrolled in LANCER, a Phase II/III Outcomes Trial in High-risk Patients Hospitalized with COVID-19
TSX:CRDL OTCQX:CRTPF FSE:CT9
